Susanna Brighenti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1696208/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell, 2020, 183, 158-168.e14.	13.5	1,561
2	Phenylbutyrate induces LL-37-dependent autophagy and intracellular killing of <i>Mycobacterium tuberculosis</i> in human macrophages. Autophagy, 2015, 11, 1688-1699.	4.3	162
3	MAIT cell activation and dynamics associated with COVID-19 disease severity. Science Immunology, 2020, 5, .	5.6	147
4	Significant Effects of Oral Phenylbutyrate and Vitamin D3 Adjunctive Therapy in Pulmonary Tuberculosis: A Randomized Controlled Trial. PLoS ONE, 2015, 10, e0138340.	1.1	125
5	Major alterations in the mononuclear phagocyte landscape associated with COVID-19 severity. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	104
6	Compartmentalization of Immune Responses in Human Tuberculosis. American Journal of Pathology, 2009, 174, 2211-2224.	1.9	99
7	Local Immune Responses in Human Tuberculosis: Learning From the Site of Infection. Journal of Infectious Diseases, 2012, 205, S316-S324.	1.9	78
8	Progression of clinical tuberculosis is associated with a Th2 immune response signature in combination with elevated levels of SOCS3. Clinical Immunology, 2014, 151, 84-99.	1.4	63
9	B in TB: B Cells as Mediators of Clinically Relevant Immune Responses in Tuberculosis. Clinical Infectious Diseases, 2015, 61, S225-S234.	2.9	60
10	Modeling <i>Mycobacterium tuberculosis</i> early granuloma formation in experimental human lung tissue. DMM Disease Models and Mechanisms, 2014, 7, 281-8.	1.2	53
11	High-dimensional profiling reveals phenotypic heterogeneity and disease-specific alterations of granulocytes in COVID-19. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	52
12	Pulmonary tuberculosis patients with a vitamin D deficiency demonstrate low local expression of the antimicrobial peptide LL-37 but enhanced FoxP3+ regulatory T cells and IgG-secreting cells. Clinical Immunology, 2015, 156, 85-97.	1.4	51
13	Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials. Vaccine, 2017, 35, 1652-1661.	1.7	47
14	Vitamin D and tuberculosis: where next?. Journal of Internal Medicine, 2018, 284, 145-162.	2.7	43
15	Daily adjunctive therapy with vitamin <scp>D</scp> ₃ and phenylbutyrate supports clinical recovery from pulmonary tuberculosis: a randomized controlled trial in Ethiopia. Journal of Internal Medicine, 2018, 284, 292-306.	2.7	42
16	Inhibition of Tissue Matrix Metalloproteinases Interferes with Mycobacterium tuberculosis-Induced Granuloma Formation and Reduces Bacterial Load in a Human Lung Tissue Model. Frontiers in Microbiology, 2017, 8, 2370.	1.5	39
17	Prime-Boost Vaccination with rBCC/rAd35 Enhances CD8+ Cytolytic T-Cell Responses in Lesions from Mycobacterium Tuberculosis-Infected Primates. Molecular Medicine, 2012, 18, 647-658.	1.9	36
18	SARS oVâ€2â€specific humoral and cellular immunity persists through 9 months irrespective of COVIDâ€19 severity at hospitalisation. Clinical and Translational Immunology, 2021, 10, e1306.	1.7	36

SUSANNA BRIGHENTI

#	Article	IF	CITATIONS
19	Perspectives for personalized therapy for patients with multidrugâ€resistant tuberculosis. Journal of Internal Medicine, 2018, 284, 163-188.	2.7	33
20	BCG-specific IgG-secreting peripheral plasmablasts as a potential biomarker of active tuberculosis in HIV negative and HIV positive patients. Thorax, 2013, 68, 269-276.	2.7	32
21	Polarization of Human Monocyte-Derived Cells With Vitamin D Promotes Control of Mycobacterium tuberculosis Infection. Frontiers in Immunology, 2019, 10, 3157.	2.2	32
22	Prostaglandin E ₂ suppresses hCAP18/LLâ€37 expression in human macrophages <i>via</i> EP2/EP4: implications for treatment of <i>Mycobacterium tuberculosis</i> infection. FASEB Journal, 2018, 32, 2827-2840.	0.2	30
23	Induction and regulation of CD8+ cytolytic T cells in human tuberculosis and HIV infection. Biochemical and Biophysical Research Communications, 2010, 396, 50-57.	1.0	28
24	A 3D Human Lung Tissue Model for Functional Studies on Mycobacterium tuberculosis Infection. Journal of Visualized Experiments, 2015, , .	0.2	27
25	Polarization of M1 and M2 Human Monocyte-Derived Cells and Analysis with Flow Cytometry upon Mycobacterium tuberculosis Infection. Journal of Visualized Experiments, 2020, , .	0.2	26
26	Increased (6 exon) interleukin-7 production after M. tuberculosis infection and soluble interleukin-7 receptor expression in lung tissue. Genes and Immunity, 2011, 12, 513-522.	2.2	24
27	Plasmacytoid Dendritic Cells Infiltrate the Skin in Positive Tuberculin Skin Test Indurations. Journal of Investigative Dermatology, 2012, 132, 114-123.	0.3	24
28	Peptide microarray-based characterization of antibody responses to host proteins after bacille Calmette–Guérin vaccination. International Journal of Infectious Diseases, 2017, 56, 140-154.	1.5	21
29	Vitamin D3 Status and the Association with Human Cathelicidin Expression in Patients with Different Clinical Forms of Active Tuberculosis. Nutrients, 2018, 10, 721.	1.7	20
30	Regulation of Immunity to Tuberculosis. Microbiology Spectrum, 2016, 4, .	1.2	18
31	Enhanced CD8+ cytolytic T cell responses in the peripheral circulation of patients with sarcoidosis and non-Löfgren's disease. Respiratory Medicine, 2018, 138, S38-S44.	1.3	15
32	Targeted Nutrition in Chronic Disease. Nutrients, 2020, 12, 1682.	1.7	15
33	A new potential biomarker for childhood tuberculosis. Thorax, 2011, 66, 727-729.	2.7	14
34	Humoral immune profiling of mycobacterial antigen recognition in sarcoidosis and Löfgren's syndrome using high-content peptide microarrays. International Journal of Infectious Diseases, 2017, 56, 167-175.	1.5	13
35	Immunomodulatory Agents Combat Multidrug-Resistant Tuberculosis by Improving Antimicrobial Immunity. Journal of Infectious Diseases, 2021, 224, 332-344.	1.9	13
36	Friends and foes of tuberculosis: modulation of protective immunity. Journal of Internal Medicine, 2018, 284, 125-144.	2.7	12

SUSANNA BRIGHENTI

#	Article	IF	CITATIONS
37	Daily Nutritional Supplementation with Vitamin D3 and Phenylbutyrate to Treatment-NaÃ ⁻ ve HIV Patients Tested in a Randomized Placebo-Controlled Trial. Nutrients, 2019, 11, 133.	1.7	11
38	Vitamin D and Phenylbutyrate Supplementation Does Not Modulate Gut Derived Immune Activation in HIV-1. Nutrients, 2019, 11, 1675.	1.7	10
39	Slow radiological improvement and persistent low-grade inflammation after chemotherapy in tuberculosis patients with type 2 diabetes. BMC Infectious Diseases, 2020, 20, 933.	1.3	8
40	Immunosuppressive Features of the Microenvironment in Lymph Nodes Granulomas from Tuberculosis and HIV–Co-Infected Patients. American Journal of Pathology, 2022, 192, 653-670.	1.9	7
41	How Mycobacterium tuberculosis Manipulates Innate and Adaptive Immunity $\hat{a} \in$ ``New Views of an Old Topic. , 0, , .		5
42	The Karolinska <scp>KI</scp> /K <scp>COVID</scp> â€19 immune atlas: An open resource for immunological research and educational purposes. Scandinavian Journal of Immunology, 2022, 96, .	1.3	4
43	Host and Pathogen Communication in the Respiratory Tract: Mechanisms and Models of a Complex Signaling Microenvironment. Frontiers in Medicine, 2020, 7, 537.	1.2	3
44	IL-7δ5 protein is expressed in human tissues and induces expression of the oxidized low density lipoprotein receptor 1 (OLR1) in CD14+ monocytes. International Journal of Infectious Diseases, 2017, 59, 29-36.	1.5	2
45	Regulation of Immunity to Tuberculosis. , 2017, , 73-93.		1
46	Toward the understanding of human tuberculosis. Journal of Internal Medicine, 2018, 284, 113-115.	2.7	1